Ruvim Izikson

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older

Lisa M. Dunkle, Ruvim Izikson, P. Patriarca et al. · New England Journal of Medicine · 2017 · 286 citations

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin

Madhusudan Rajendran, Raffael Nachbagauer, Megan E. Ermler et al. · mBio · 2017 · 161 citations · Full text

Life Sciences, Immunology, Infectious Diseases +11

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial

John J. Treanor, Hana M. El Sahly, James C. King et al. · Vaccine · 2011 · 160 citations

Veterinary Medicine, Immunology, Infectious Diseases +13

Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans

Raffael Nachbagauer, Angela Choi, Ruvim Izikson et al. · mBio · 2016 · 155 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age☆

Roger Baxter, P. Patriarca, Kathleen Ensor et al. · Vaccine · 2011 · 109 citations

Veterinary Medicine, Immunology, Infectious Diseases +13